Drugs / pGA2/JS2
pGA2/JS2
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00301184 | Apr 2006 → Dec 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00043511 | ? → Apr 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00820846 | Jan 2009 → Aug 2012 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pGA2/JS2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00043511 ↗ |
| Known as | pGA2/JS7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00301184 ↗ |
| Known as | pGA2/JS7 DNA | “Biological: pGA2/JS7 DNA” NCT00301184 ↗ |
| Modality | Vaccine | “The vaccine being tested in this study is a DNA vaccine.” NCT00043511 ↗ |
| Route | Intramuscular | “All vaccinations are administered by intramuscular (IM) injection” NCT00043511 ↗ |